243 related articles for article (PubMed ID: 26696550)
41. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
42. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma.
Zhang ZW; Newcomb P; Hollowood A; Feakins R; Moorghen M; Storey A; Farthing MJ; Alderson D; Holly J
Clin Cancer Res; 2003 Jun; 9(6):2151-6. PubMed ID: 12796380
[TBL] [Abstract][Full Text] [Related]
43. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
44. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
45. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
Duo-Ji MM; Ci-Ren BS; Long ZW; Zhang XH; Luo DL
Oncotarget; 2017 Jun; 8(23):37896-37911. PubMed ID: 28099947
[TBL] [Abstract][Full Text] [Related]
46. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
47. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
48. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
49. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
[TBL] [Abstract][Full Text] [Related]
50. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
51. Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study.
Eren OO; Ozturk MA; Sonmez OU; Oyan B
Am J Ther; 2016; 23(6):e1493-e1497. PubMed ID: 25397587
[TBL] [Abstract][Full Text] [Related]
52. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
53. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Meulendijks D; Rozeman EA; Cats A; Sikorska K; Joerger M; Deenen MJ; Beijnen JH; Schellens JHM
Pharmacogenomics J; 2017 Oct; 17(5):441-451. PubMed ID: 27995989
[TBL] [Abstract][Full Text] [Related]
55. Association of TP53 gene codon 72 polymorphism with endometriosis in Mexican women.
Gallegos-Arreola MP; Figuera-Villanueva LE; Puebla-Pérez AM; Montoya-Fuentes H; Suarez-Rincon AE; Zúñiga-González GM
Genet Mol Res; 2012 May; 11(2):1401-8. PubMed ID: 22653586
[TBL] [Abstract][Full Text] [Related]
56. [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis].
Chen WC; Wu G; Zhang W; Zhu YZ; Zhou Y; Zhang H; Xia XB; Sun PC
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3420-3425. PubMed ID: 30440137
[No Abstract] [Full Text] [Related]
57. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel-based regimens as first-line treatment in advanced gastric cancer.
Guo Z; Wang X; Lin R; Chen L; Fan N; Chen Y; Lin J; Yu J
J Chemother; 2015 Feb; 27(2):94-8. PubMed ID: 24548091
[TBL] [Abstract][Full Text] [Related]
59. Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.
Sato K; Kunisaki C; Kosaka T; Takagawa R; Takahashi M; Izumisawa Y; Miyamoto H; Sato S; Tanaka Y; Yamaguchi N; Kimura J; Ono HA; Makino H; Akiyama H; Endo I
Cancer Chemother Pharmacol; 2017 Nov; 80(5):939-943. PubMed ID: 28913549
[TBL] [Abstract][Full Text] [Related]
60. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]